Evidence map›Paper›PMID 33162971›Full record

ArticleFrontiers in immunology2020

Cancer-Associated Fibroblasts-Derived Exosomes Suppress Immune Cell Function in Breast Cancer via the miR-92/PD-L1 Pathway.

Dongwei Dou, Xiaoyang Ren, Mingli Han, Xiaodong Xu, Xin Ge, Yuanting Gu, Xinxing Wang

RetractedOpen access · goldAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 125 papers.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed
9.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 172 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Dongwei DouDepartment of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xiaoyang RenDepartment of Information, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Mingli HanDepartment of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xiaodong XuDepartment of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xin GeDepartment of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yuanting GuDepartment of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xinxing WangDepartment of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
First Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer-associated fibroblasts (CAFs) are an essential component in the tumor microenvironment and have been reported to contribute to tumor progression through many mechanisms; however, the detailed mechanism underlying the immune-suppression effect of CAFs is not clearly defined. In this study, human breast cancer-derived CAFs were cultured, and CAF-derived exosomes in a culture medium were isolated. Using a miRNA profiles assay, we identify a significantly higher level of microRNA-92 isolated in CAFs exosomes. After treatment by CAF-derived exosomes, breast cancer cells express higher programmed cell death receptor ligand 1 (PD-L1), accompanied with increased miR-92 expression. Increased PD-L1 expression, which was induced by CAF-derived exosomes, significantly promotes apoptosis and impaired proliferation of T cells. The underlying mechanism of this effect was studied, proliferation and migration of breast cancer cells were increased after the transfection of miR-92, LATS2 was recognized as a target gene of miR-92, and further confirmed by a luciferase assay. Immunoprecipitation showed that LATS2 can interact with YAP1, chromatin immunoprecipitation confirmed that after nuclear translocation YAP1 could bind to the enhancer region of PD-L1 to promotes transcription activity. Furthermore, the animal study confirmed that CAFs significantly promoted tumor progression and impaired the function of tumor-infiltrated immune cells

Indexed as

ImmunomodulationAdaptor Proteins, Signal TransducingAnimalsB7-H1 AntigenBiomarkersBreast NeoplasmsCancer-Associated FibroblastsCell Line, TumorCell MovementCell ProliferationExosomesFemaleFluorescent Antibody TechniqueGene Expression Regulation, NeoplasticHumansMicroRNAsAdaptor Proteins, Signal TransducingB7-H1 AntigenBiomarkersCD274 protein, humanMicroRNAsMIRN92 microRNA, humanTranscription FactorsYAP1 protein, humanYAP-Signaling Proteinsbreast cancerCAFmiR-92PD-L1YAP1

Identifiers

PMID33162971
PMCPMC7581790
OpenAlexW3092240599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.